Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
← catalyst calendarNCT07400588 · readout ≤ 42 d
Sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics (industry) · GPCR — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
58actual
Sites
16
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-01 | actual | When the study began enrolling |
| Primary completion | Sep 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obese
- Obesity
- Obesity Type 2 Diabetes Mellitus
- Weight Loss
Interventions
- Drug: Aleniglipron
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFIncidence, severity and relationship of AEs/SAEs
measured Baseline to week 31
Assessment of vital signs
measured Baseline to week 31
Assessment of laboratory measures
measured Baseline to week 31
Assessment of Electrocardiograms (ECG)
measured Baseline to week 31
Permalink · GPCR's whole pipeline · Catalyst calendar · Every registered study · What changed